Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tevogen Bio Holdings Inc (TVGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: TVGNW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.67 | 52 Weeks Range 0.01 - 0.15 | Updated Date 06/12/2025 |
52 Weeks Range 0.01 - 0.15 | Updated Date 06/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -578.29% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 20805703 |
Shares Outstanding - | Shares Floating 20805703 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tevogen Bio Holdings Inc
Company Overview
History and Background
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company specializing in developing immunotherapies for viral infections, cancers, and autoimmune diseases. Founded in 2010, the company has focused on developing its proprietary T cell-based immunotherapy platform.
Core Business Areas
- Immunotherapy Development: Focused on developing allogeneic T cell immunotherapies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its lead product candidate, TVGN-489, for various indications.
- Manufacturing: Developing in-house manufacturing capabilities for T cell therapies.
Leadership and Structure
Dr. Jenny Lin is the Founder and CEO. The company has a management team with expertise in immunology, oncology, and clinical development.
Top Products and Market Share
Key Offerings
- TVGN-489: Tevogen's lead product candidate, an allogeneic T cell immunotherapy targeting viral infections. It is currently in clinical development, so there is no market share or revenue yet. Competitors include companies developing antiviral therapies and other immunotherapies such as Gilead Sciences (GILD) and Regeneron (REGN).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth due to advancements in cell and gene therapies and increasing prevalence of cancer and autoimmune diseases.
Positioning
Tevogen is positioning itself as a leader in the allogeneic T cell immunotherapy space. Its competitive advantage lies in its proprietary T cell platform.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of dollars. Tevogen is targeting a portion of this TAM with its specific therapeutic focus. The TAM will vary considerably depending on the success of their products and clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary T cell immunotherapy platform
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited clinical trial data
- Dependence on single product candidate (TVGN-489)
- High cash burn rate
- Small market capitalization
- Stock has volatile returns
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- FDA Fast Track designation
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Financial market volatility
Competitors and Market Share
Key Competitors
- GILD
- REGN
- BMY
- MRNA
Competitive Landscape
Tevogen faces strong competition from established pharmaceutical companies with significant resources. Its success depends on demonstrating the superiority of its T cell immunotherapy platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's early stage.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing TVGN-489 through clinical trials and exploring partnerships.
Summary
Tevogen Bio Holdings is an early-stage biotech firm with a novel T-cell immunotherapy platform. Its success hinges on positive clinical trial results for TVGN-489. The company faces significant competition and financial risks. Partnerships and regulatory approvals are crucial for its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Due to the limited data for Tevogen Bio Holdings, accuracy of some assertions may be limited.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tevogen Bio Holdings Inc
Exchange NASDAQ | Headquaters Warren, NJ, United States | ||
IPO Launch date 2022-01-03 | Co-Founder, CEO & Chairperson Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://tevogen.com |
Full time employees 18 | Website https://tevogen.com | ||
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.